SICHUAN KELUN PHARMACEUTICAL CO.,LTD.

About us

Kelun Pharmaceutical, as a leading enterprise in China's pharmaceutical industry, offers a broad and technologically advanced product portfolio. In the field of intravenous therapies, the company has achieved a major breakthrough in safe infusion technology with its self-developed KeLiBag® (the domestically and internationally first upright soft-bag infusion) and ready-to-use high-end infusions (such as total parenteral nutrition multi-chamber bags and antibiotic premixed dual-chamber bags). The products feature high safety, cost-effectiveness, and environmental advantages, and are widely used in emergency medical settings and exported to more than 50 countries and regions.
In the antibiotic sector, through its subsidiary Chuanning Biotech, Kelun has built a complete value chain—from intermediates to active pharmaceutical ingredients (APIs) to formulations—overcoming the challenges of "three wastes" governance and becoming a green environmental benchmark.
In innovative medicines, Kelun Botai focuses on antibody–drug conjugate (ADC) development. Its TROP2 ADC, Jaitelai®, and PD-L1 monoclonal antibody Ketailai® have been approved for market, providing new options for tumor treatment. The company has also reached a multi-billion-dollar licensing collaboration with Merck & Co, establishing international leadership in innovation.
Moreover, the company is expanding into the anti-aging arena, developing various nutraceutical ingredients and forming a full-chain product matrix.